Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | TYK2 | P29597 | 2/20 | 0.53 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.53 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.53 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.53 |
| ▸ | MARK3 | P27448 | 2/20 | 0.53 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571770 | 0.87 | MARK3 (0.51) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL1571728 | 0.86 | TBK1 (0.58) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL29370869 | 0.80 | CDK1 (0.63) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL13574088 | 0.80 | CDK1 (0.51) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL1634550 | 0.80 | CDK1 (0.59) | CDK1JAK2JAK3RIPK2LRRK2 | |
| SCHEMBL13901171 | 0.80 | TBK1 (0.66) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL1049234 | 0.78 | P2RX3 (0.54) | KDREGFR | |
| SCHEMBL13336182 | 0.77 | ACVR1 (0.50) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL1571603 | 0.76 | CDK1 (0.51) | TBK1NTRK1CSF1RTYK2NUAK1 | |
| SCHEMBL13336327 | 0.76 | CDK1 (0.51) | TBK1NTRK1CSF1RTYK2NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| EP-2125755-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis Ag (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | TBK1 493/4885NTRK1 2015/4885CSF1R 1514/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | TBK1 792/4885NTRK1 2584/4885CSF1R 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.